Three doses of the commercially available hepatitis B vaccine were administered to each of 43 anti-hepatitis B surface antigen antibody-negative children (including 32 hemophiliacs) who were regularly receiving blood product transfusions. Forty-two (98%) of them had demonstrable anti-hepatitis B surface antigen antibody in their serum, indicating that this group of patients responds favorably to the vaccine.
|Original language||English (US)|
|Number of pages||3|
|Journal||Pediatric infectious disease|
|State||Published - Jan 1 1986|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Microbiology (medical)